Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
30 April 2014 - 6:01AM
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty
biopharmaceutical company which develops botulinum toxin products
for use in aesthetic and therapeutic indications, today announced
that the company will release first quarter 2014 financial results
on Tuesday, May 13, 2014 after the close of market. Revance will
host a conference call and a live Internet webcast at 1:30pm
PT/4:30pm ET on the same day to discuss the results and provide a
business and clinical update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers, or from the webcast link in the
investor relations section of the Company's website at:
www.revance.com. Participants should allow approximately five to 10
minutes prior to the call's start time to visit the site and to
download any streaming media software needed to listen to the
Internet webcast. The webcast will be available in the Investor
Relations section on the Company's website for 30 days following
the completion of the call.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company focused on the
development, manufacturing and commercialization of novel botulinum
toxin products for multiple aesthetic and therapeutic applications.
The Company is leveraging its proprietary portfolio of botulinum
toxin compounds combined with its patented TransMTS® peptide
delivery system to address unmet needs in the large and growing
aesthetic and therapeutic botulinum toxin market. Revance's
proprietary TranMTS technology enables transcutaneous delivery of
botulinum toxin A, eliminating the need for injections. The
Company's lead product candidate, RT001, is a topical formulation
of botulinum toxin type A, which has the potential to be the first
commercially-available non-injectable dose form. RT001 is being
evaluated in a broad clinical program that includes aesthetic
indications such as crow's feet lines (wrinkles around the eyes)
and therapeutic indications such as hyperhidrosis (excessive
sweating) and migraine headache. Revance's second product
candidate, RT002, is a novel, injectable formulation of botulinum
toxin type A designed to be more targeted and longer lasting than
currently available botulinum toxin injectable products.
"Revance Therapeutics", TransMTS® and the Revance logo are
registered trademarks of Revance Therapeutics, Inc. All other
trademarks or registered trademarks are the property of their
respective owners.
For more information, please visit: www.revance.com.
CONTACT: Westwicke Partners
Ana Petrovic
(415) 513-1281
ana.petrovic@westwicke.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024